Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

This article has a correction. Please see:

Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy - September 01, 2022

PDF +
Supplementary
Material

Oncolytic and local immunotherapy

Original research

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

Online download statistics by month:

Online download statistics by month: May 2022 to March 2024

	Abstract	Full	Pdf
May 2022	389	422	237
Jun 2022	529	580	286
Jul 2022	312	322	125
Aug 2022	248	252	69
Sep 2022	266	273	276
Oct 2022	245	249	70
Nov 2022	166	166	76
Dec 2022	160	160	90
Jan 2023	141	141	94
Feb 2023	135	137	84
Mar 2023	93	93	55
Apr 2023	105	105	79
May 2023	87	88	58
Jun 2023	87	87	52
Jul 2023	88	88	67
Aug 2023	103	105	57
Sep 2023	130	130	75
Oct 2023	130	130	62
Nov 2023	156	158	44
Dec 2023	118	120	69
Jan 2024	107	109	71
Feb 2024	102	102	54
Mar 2024	132	132	109
Total	4029	4149	2259